ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2757

Secondary Efficacy Endpoints: Results from a Phase 3 Study Comparing ABP 501 with Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis

Alan K. Matsumoto1, Karel Pavelka2, Warren Rizzo3, Ramesh Gupta4, William Shergy5, Pawel Heycaj6, Nan Zhang7 and Primal P. Kaur8, 1Rheumatology, Arthritis & Rheumatism Assoc, Wheaton, MD, 2Charles University, Prague, Czech Republic, 3Advanced Arthritis Care & Research, Scottsdale, AZ, 4Private Practice, Rheumatology, Memphis, TN, 5RANA Clinical Research Center, Huntsville, AL, 6Rheumatology and Clinical Immunology, PoznaƱ University of Medical Sciences, Poznan, Poland, 7Biosimilars, Amgen, Inc., Thousand Oaks, CA, 8Amgen, Inc., Thousand Oaks, CA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Adalimumab and biosimilars

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 10, 2015

Session Title: Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

ABP 501 is being developed as a biosimilar candidate to adalimumab (Humira®), a fully human recombinant monoclonal antibody. Evidence from analytical and pharmacokinetic comparisons indicates that ABP 501 is highly similar to adalimumab. Primary efficacy endpoints and safety results from a phase 3 study comparing ABP 501 with adalimumab in subjects with rheumatoid arthritis (RA) are reported separately. Here we report the secondary efficacy endpoints of the study. The objective was to evaluate and compare American College of Rheumatology 20% response criteria (ACR20), ACR50, and ACR70, as well as the change from baseline in Disease Activity Score in 28 joints using C-reactive protein (DAS28-CRP) over weeks 2–24 for ABP 501 and adalimumab based on results from a phase 3 study.

Methods:

This was a randomized, double-blind, active-controlled study in adult subjects with moderate to severe RA who had an inadequate response to methotrexate. Subjects were randomized in a 1:1 ratio (ABP 501: n=264; adalimumab: n=262) to receive either ABP 501 or adalimumab 40 mg subcutaneously every 2 weeks. The primary endpoint was risk ratio (RR) of ACR20 assessed at week 24 with a safety follow-up to week 26 (end of study). Here we report descriptive results of the secondary efficacy endpoints that included risk difference (RD) of ACR20, RR of ACR50 and ACR70, and difference in change from baseline of DAS28-CRP over the entire study.

Results:

Baseline characteristics were well balanced between groups. The table shows the response rate for ACR20, ACR50, and ACR70 throughout the study. At week 24, the RD of ACR20, ACR50 and ACR70 for ABP 501 vs adalimumab was 2.60% (2-sided 90% CI, –3.728% to 8.936%), –2.84% (90% CI, –10.220 to 4.547) and 3.15% (90% CI, –3.177 to 9.470), respectively. The RR of ACR50 and ACR70 was 0.95 (90% CI, 0.819–1.097) and 1.13 (90% CI, 0.872–1.464), respectively, at week 24. The differences in mean change from baseline in DAS28-CRP between ABP 501 and adalimumab were –0.08 (90% CI, –0.24 to 0.08) at week 8, –0.09 (90% CI, –0.26 to 0.07) at week 12, –0.09 (90% CI, –0.25 to 0.08) at week 18, and –0.01 (90% CI, –0.18 to 0.17) at week 24. The overall safety and immunogenicity profile of ABP 501 was comparable to that of adalimumab and is reported separately.

Table. Response Rate (%) of ACR20, ACR50, and ACR70 by Visit and Treatment

Week

ACR   20

ACR   50

ACR   70

ABP   501

adalimumab

ABP   501

adalimumab

ABP   501

adalimumab

2

35.4

24.5

11.0

6.2

0.8

1.9

4

51.5

45.0

19.5

17.8

5.1

3.9

8

63.5

62.5

31.1

28.5

10.4

10.2

12

74.6

65.5

41.3

43.5

15.3

13.3

18

77.3

75.9

50.0

47.2

19.6

22.8

24

74.6

72.4

49.2

52.0

26.0

22.9

 Conclusion:

Along with the primary endpoint, these data support the results that efficacy of ABP 501 was similar to adalimumab.


Disclosure: A. K. Matsumoto, Abbvie, Amgen, Pfizer, Takeda, 2; K. Pavelka, None; W. Rizzo, None; R. Gupta, None; W. Shergy, None; P. Heycaj, None; N. Zhang, Amgen, 3; P. P. Kaur, Amgen, 3.

To cite this abstract in AMA style:

Matsumoto AK, Pavelka K, Rizzo W, Gupta R, Shergy W, Heycaj P, Zhang N, Kaur PP. Secondary Efficacy Endpoints: Results from a Phase 3 Study Comparing ABP 501 with Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/secondary-efficacy-endpoints-results-from-a-phase-3-study-comparing-abp-501-with-adalimumab-in-subjects-with-moderate-to-severe-rheumatoid-arthritis/. Accessed May 16, 2022.
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/secondary-efficacy-endpoints-results-from-a-phase-3-study-comparing-abp-501-with-adalimumab-in-subjects-with-moderate-to-severe-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.